Deals, Partnering

Algeta signs global agreement with Bayer Schering Pharma for development and commercialization of Alpharadin for bone metastases

Posted on 03 September 2009

Tags: ,

Algeta has an option for up to 50% co-promotion with Bayer in the United States under a profit-share arrangement. Bayer will commercialize Alpharadin globally and pay tiered double-digit royalties on net sales in markets where there is no co-promotion.

Print Friendly, PDF & Email

Leave a Reply

 

cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif